Improve Anti-alveolar Echinococcosis Efficacy of Albendazole by a Novel Nano-crystalline Formulation with Enhanced Oral Bioavailability

(Supporting Information)

Chunhui Hu, †, ‡ Zhengsheng Liu, † Chengyu Liu, † Yaogang Zhang, ♥ Haining Fan, I, * Feng Qian †, *

[†] School of Pharmaceutical Sciences, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, and Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology (Ministry of Education), Tsinghua University, Beijing 100084, P. R. China.

[‡] Medical College, Qinghai University, Qinghai, 810001, P. R. China.

[▽] Qinghai Research Key Laboratory for Echinococcosis, Affiliated Hospital of Qinghai University, Qinghai, 810001, P. R. China.

Department of Hepatopancreatobiliary Surgery Affiliated Hospital of Qinghai University, Qinghai, 810001, P. R. China.

Number of pages: 5 Number of figures: 3 Number of tables: 1

Correspondence and requests for materials should be addressed:

H.F. (Email: fanhaining@medmail.com.cn)
F.Q. (Email: qianfeng@tsinghua.edu.cn)

Manuscript for ACS Infectious Diseases




Figure S1. Effect of P188 on the supersaturation of ABZ in FaSSIF.




Figure S2. Equilibrium solubility of ABZ at different concentrations of P188.




Figure S3. The drug concentration-time curve of ABZ-SO₂ from Albenda® and NC.

Table S1. Pharmacokinetics parameters of ABZ-SO $_2$ from Albenda $^{\circledR}$ and NC in vivo

Analyte		Albenda [®]	NC
	$T_{\max}(\mathbf{h})$	13.3 ± 12.4	7.2 ± 8.2
ABZ-SO ₂	$C_{max} (ng/mL)$	835.2 ± 1091.9	2402.1 ± 1154.2
	AUC (hr/ng/mL)	7546.5 ± 10812.5	20116.9 ± 8416.2